WARSAW,
Ind., March 10, 2022 /PRNewswire/ -- Zimmer
Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical
technology leader, today announced the release of WalkAI™, a
dynamic artificial intelligence (AI) model that identifies
patients1 who are predicted to have a lower gait speed
outcome at 90 days after hip or knee surgery. WalkAI, the company's
first AI-based solution, adds powerful predictive analytic
capabilities to ZBEdge™, a suite of integrated smart, digital and
robotic technologies purposefully engineered to deliver
transformative data-powered clinical insights with the goal of
improving patient outcomes.
WalkAI uses a proprietary algorithm to analyze a patient's
mobility to generate a personalized daily prediction of their gait
(walking) speed at 90 days after surgery. The daily prediction is
compared to anonymized, real-world data from the extensive ZBEdge
database to identify when a patient's recovery may not be on track
based on predicted low gait speed.
"Using a proprietary, Zimmer Biomet-developed artificial
intelligence algorithm, WalkAI is the orthopedic industry's first
and only AI-based model to create daily, personalized predictions
and identify patients who may be exceptions to typical recovery
curves in an effort to help surgeons mitigate or minimize poor
outcomes," said Liane Teplitsky,
President, Global Robotics and Technology & Data Solutions,
Zimmer Biomet. "WalkAI is built from our wealth of anonymized
ZBEdge data and is the first model to demonstrate our unique
capability to deliver actionable predictions by connecting
real-world data and AI through ZBEdge products and
experiences."
WalkAI integrates with the mymobility® Care
Management Platform, which collects patient gait data, through
their iPhone®2 and when necessary, provides
the WalkAI notification to healthcare professionals through the
mymobility clinician dashboard.
"Our strategic prioritization and investment in R&D has
solidified our position as an innovator in our space with
breakthrough technologies like Persona IQ®, a
first-to-world smart knee implant, mymobility Care Management
Platform, ROSA® Robotics, and now, WalkAI, the first
AI-based model in orthopedics to create daily personalized outcome
predictions based on a patient's gait recovery," said Ivan Tornos,
Chief Operating Officer, Zimmer Biomet. "ZBEdge is realizing our
bold vision of an interconnected ecosystem of digital and robotic
technologies by sharing data and unlocking clinical insights, which
is now enhanced by artificial intelligence modeling."
A first step for Zimmer Biomet's AI platform, WalkAI has been
rolled out globally to a select group of mymobility users and will
be widely available as part of ZBEdge by the end of March 2022. For more information on WalkAI, visit
www.zimmerbiomet.com/zbedge.
About the Company
Zimmer Biomet is a global medical
technology leader with a comprehensive portfolio designed to
maximize mobility and improve health. We seamlessly transform the
patient experience through our innovative products and suite of
integrated digital and robotic technologies that leverage data,
data analytics and artificial intelligence.
With 90+ years of trusted leadership and proven expertise,
Zimmer Biomet is positioned to deliver the highest quality
solutions to patients and providers. Our legacy continues to come
to life today through our progressive culture of evolution and
innovation.
For more information about our product portfolio, our operations
in 25+ countries and sales in 100+ countries or about joining our
team, visit www.zimmerbiomet.com or follow Zimmer Biomet on
Twitter at www.twitter.com/zimmerbiomet.
Cautionary Statement Regarding Forward-Looking
Statements
This news release contains forward-looking
statements within the meaning of the safe harbor provisions of the
Private Securities Litigation Reform Act of
1995. Forward-looking statements include, but are not limited
to, statements concerning Zimmer Biomet's expectations, plans,
prospects, and product and service offerings, including new product
launches and potential clinical successes. Such statements are
based upon the current beliefs and expectations of management and
are subject to significant risks, uncertainties and changes in
circumstances that could cause actual outcomes and results to
differ materially. For a list and description of some of such
risks and uncertainties, see Zimmer Biomet's periodic reports filed
with the U.S. Securities and Exchange Commission
(SEC). These factors should not be construed as exhaustive and
should be read in conjunction with the other cautionary statements
that are included in Zimmer Biomet's filings with the
SEC. Forward-looking statements speak only as of the date they
are made, and Zimmer Biomet disclaims any intention or obligation
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise. Readers
of this news release are cautioned not to rely on these
forward-looking statements, since there can be no assurance that
these forward-looking statements will prove to be
accurate. This cautionary statement is applicable to all
forward-looking statements contained in this news release.
Apple and iPhone are registered trademarks of Apple, Inc.
1 Patients
are assessed and identified by WalkAI from day 15 after surgery
through day 40 after surgery. During this time period it is
predicting what their gait speed will be at day 90 after
surgery.
2 WalkAI utilizes patient gait data collected for
patients using the mymobility application on an iPhone. It is not
supported for patients using mymobility on Android or through their
browser.
|
Media
|
|
Meredith
Weissman
|
|
(703)
346-3127
|
|
meredith.weissman@zimmerbiomet.com
|
|
|
|
Investors
|
|
Ezgi Yagci
|
Keri Mattox
|
(617)
549-2443
|
(203)
399-0856
|
ezgi.yagci@zimmerbiomet.com
|
keri.mattox@zimmerbiomet.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/zimmer-biomet-debuts-walkai-artificial-intelligence-model-to-predict-post-operative-recovery-progress-301499594.html
SOURCE Zimmer Biomet Holdings, Inc.